Arineta
Company Information
Address: 15 Halamish St. Caesarea, IL 3088900
Products
SpotLight/SpotLight Duo (with DLIR option)
Released:10/13/2023
Regulator:FDA
SpotLight/SpotLight Duo (with DLIR option) is a CT scanner that produces cross-sectional images of the body, including cardiovascular and thoracic anatomies. It uses a dual-tube CT system and advanced deep learning reconstruction to enhance image quality while reducing noise. This helps clinicians obtain clearer diagnostic images for disease detection and therapy planning.
View detailsSpotLight/SpotLight Duo with Low Dose Lung Cancer Screening Option
Released:1/13/2025
Regulator:FDA
The SpotLight/SpotLight Duo with Low Dose Lung Cancer Screening Option is a computed tomography (CT) X-ray system developed by Arineta Ltd. It produces detailed cross-sectional images of the body, especially of the cardiovascular and thoracic areas, enabling clinicians to screen and diagnose lung cancer using low-dose CT protocols. This device helps physicians detect lung nodules and other thoracic abnormalities with reduced radiation exposure, supporting effective lung cancer screening programs following clinical guidelines.
View detailsSpotLight / SpotLight Duo with Low Dose Lung Cancer Screening Option
Released:4/15/2025
Regulator:FDA
The SpotLight / SpotLight Duo with Low Dose Lung Cancer Screening Option is a CT X-ray system that produces cross-sectional images of the body, particularly the cardiovascular and thoracic regions. It includes protocols for low dose CT scans aimed at lung cancer screening, ensuring minimal radiation exposure while maintaining image quality. This device assists clinicians in diagnosing lung cancer and planning related therapies, utilizing advanced image reconstruction algorithms and adaptable scan techniques for patients of various sizes.
View detailsReady to Sharpen Your Edge?
Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.
We respect your privacy. Unsubscribe at any time.